NASDAQ:CGIX - Cancer Genetics Stock Price, Forecast & News

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

Cancer Genetics Inc (NASDAQ:CGIX) announced its quarterly earnings data on Wednesday, November, 20th. The medical research company reported ($0.32) earnings per share for the quarter. The medical research company earned $2.07 million during the quarter. Cancer Genetics had a negative net margin of 59.28% and a negative return on equity of 139.59%. View Cancer Genetics' Earnings History.

Cancer Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Cancer Genetics.

Press coverage about CGIX stock has been trending very positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cancer Genetics earned a coverage optimism score of 3.9 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Cancer Genetics.

Cancer Genetics saw a decline in short interest in December. As of December 31st, there was short interest totalling 81,400 shares, a decline of 39.6% from the December 15th total of 134,800 shares. Based on an average trading volume of 690,300 shares, the short-interest ratio is presently 0.1 days. Currently, 4.4% of the shares of the company are sold short. View Cancer Genetics' Current Options Chain.

Some companies that are related to Cancer Genetics include PotNetwork (POTN), Miragen Therapeutics (MGEN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), OpGen (OPGN), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), Synergy Pharmaceuticals (SGYP), Activision Blizzard (ATVI), Novavax (NVAX), Gilead Sciences (GILD), Ford Motor (F), TransEnterix (TRXC), Melinta Therapeutics (MLNT), Sorrento Therapeutics (SRNE) and NovaBay Pharmaceuticals (NBY).

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CGIX stock can currently be purchased for approximately $4.45.

Cancer Genetics has a market capitalization of $9.35 million and generates $27.47 million in revenue each year. Cancer Genetics employs 150 workers across the globe.View Additional Information About Cancer Genetics.

The official website for Cancer Genetics is http://www.cancergenetics.com/.

Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]